650 related articles for article (PubMed ID: 36951443)
1. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Zou X; Xu Q; You R; Yin G
Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
Lin LW; Yan LY; Ke K; Yang WZ; Lin JQ; Huang N
Brachytherapy; 2023; 22(6):858-871. PubMed ID: 37574351
[TBL] [Abstract][Full Text] [Related]
5. Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study.
Cai M; Huang W; Huang J; Shi W; Guo Y; Liang L; Zhou J; Lin L; Cao B; Chen Y; Zhou J; Zhu K
Front Immunol; 2022; 13():848387. PubMed ID: 35300325
[TBL] [Abstract][Full Text] [Related]
6. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
[TBL] [Abstract][Full Text] [Related]
7. Transarterial chemoembolization plus immune checkpoint inhibitor as postoperative adjuvant therapy for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter cohort study.
Yuan L; Feng J; Zhang Y; Lu C; Xu L; Liang C; Liu Z; Mao F; Xiang Y; Wang W; Wang K; Cheng S
Eur J Surg Oncol; 2023 Jul; 49(7):1226-1233. PubMed ID: 36739252
[TBL] [Abstract][Full Text] [Related]
8. Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Xia WL; Zhao XH; Guo Y; Hu HT; Cao GS; Li Z; Fan WJ; Xu SJ; Li HL
Clin Transl Gastroenterol; 2023 May; 14(5):e00581. PubMed ID: 36920551
[TBL] [Abstract][Full Text] [Related]
9. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.
Li X; Ding X; Liu M; Wang J; Sun W; Teng Y; Xu Y; Wu H; Li W; Zhou L; Chen J
Cancer Med; 2023 Aug; 12(16):16805-16814. PubMed ID: 37387602
[TBL] [Abstract][Full Text] [Related]
10. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Fan W; Yuan G; Fan H; Li F; Wu Y; Zhao Y; Yao W; Wang Y; Xue M; Yang J; Li J
Clin Ther; 2019 Aug; 41(8):1463-1476. PubMed ID: 31303279
[TBL] [Abstract][Full Text] [Related]
11. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
[TBL] [Abstract][Full Text] [Related]
12. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation.
Yang Z; Zou R; Zheng Y; Qiu J; Shen J; Liao Y; Zhang Y; Wang C; Wang Y; Yuan Y; Li K; Zuo D; He W; Liu W; Li B; Yuan Y
Eur Radiol; 2019 Nov; 29(11):5752-5762. PubMed ID: 30993438
[TBL] [Abstract][Full Text] [Related]
13. DEM-TACE as the initial treatment could improve the clinical efficacy of the hepatocellular carcinoma with portal vein tumor thrombus: a retrospective controlled study.
Chen J; Lai L; Luo J; Wang H; Li M; Huang M
BMC Cancer; 2022 Nov; 22(1):1242. PubMed ID: 36451104
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
15. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.
Sun L; Xu X; Meng F; Liu Q; Wang H; Li X; Li G; Chen F
Front Oncol; 2022; 12():980214. PubMed ID: 36249023
[TBL] [Abstract][Full Text] [Related]
16. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study.
Yuan Y; He W; Yang Z; Qiu J; Huang Z; Shi Y; Lin Z; Zheng Y; Chen M; Lau WY; Li B; Yuan Y
Int J Surg; 2023 May; 109(5):1222-1230. PubMed ID: 37026861
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.
Chen R; Li Y; Song K; Li L; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Apr; 13(2):780-786. PubMed ID: 35557575
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
Zhu K; Chen J; Lai L; Meng X; Zhou B; Huang W; Cai M; Shan H
Radiology; 2014 Jul; 272(1):284-93. PubMed ID: 24708192
[TBL] [Abstract][Full Text] [Related]
19. Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.
Xue M; Wu Y; Zhu B; Zou X; Fan W; Li J
Am J Cancer Res; 2021; 11(12):6107-6118. PubMed ID: 35018245
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.
Xin Y; Zhang X; Liu N; Peng G; Huang X; Cao X; Zhou X; Li X
Hepatol Int; 2023 Jun; 17(3):753-764. PubMed ID: 37038024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
